全文获取类型
收费全文 | 12339篇 |
免费 | 889篇 |
国内免费 | 223篇 |
专业分类
耳鼻咽喉 | 653篇 |
儿科学 | 43篇 |
妇产科学 | 247篇 |
基础医学 | 714篇 |
口腔科学 | 340篇 |
临床医学 | 990篇 |
内科学 | 1529篇 |
皮肤病学 | 197篇 |
神经病学 | 21篇 |
特种医学 | 548篇 |
外科学 | 3370篇 |
综合类 | 1684篇 |
预防医学 | 270篇 |
眼科学 | 36篇 |
药学 | 509篇 |
中国医学 | 73篇 |
肿瘤学 | 2227篇 |
出版年
2024年 | 8篇 |
2023年 | 89篇 |
2022年 | 230篇 |
2021年 | 275篇 |
2020年 | 255篇 |
2019年 | 156篇 |
2018年 | 187篇 |
2017年 | 235篇 |
2016年 | 283篇 |
2015年 | 301篇 |
2014年 | 545篇 |
2013年 | 596篇 |
2012年 | 692篇 |
2011年 | 814篇 |
2010年 | 722篇 |
2009年 | 762篇 |
2008年 | 722篇 |
2007年 | 777篇 |
2006年 | 783篇 |
2005年 | 715篇 |
2004年 | 578篇 |
2003年 | 570篇 |
2002年 | 463篇 |
2001年 | 499篇 |
2000年 | 410篇 |
1999年 | 332篇 |
1998年 | 239篇 |
1997年 | 238篇 |
1996年 | 185篇 |
1995年 | 146篇 |
1994年 | 112篇 |
1993年 | 63篇 |
1992年 | 43篇 |
1991年 | 28篇 |
1990年 | 35篇 |
1989年 | 34篇 |
1988年 | 32篇 |
1987年 | 26篇 |
1986年 | 23篇 |
1985年 | 42篇 |
1984年 | 27篇 |
1983年 | 25篇 |
1982年 | 29篇 |
1981年 | 29篇 |
1980年 | 36篇 |
1979年 | 26篇 |
1978年 | 6篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1972年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit 下载免费PDF全文
Sharareh SeifiBabak SalimiZahra Esfahani-MonfaredRamin RadmaneshSaeed YaghoubifardSara TalebianpourAdnan Khosravi 《Asian Pacific journal of cancer prevention》2022,23(4):1155-1158
Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients with EGFR mutation received Erlova at 150 mg/day as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about 88%. Most frequent treatment related adverse events was skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors. 相似文献
3.
4.
目的探究肾透明细胞癌不同CT影像学征象对患者术后康复情况的影响。方法选取2010年1月到2014年4月我院收治的50例肾透明细胞癌患者的CT征象,进行T分期,并分析不同CT征象与患者预后关系。结果利用CT征象进行T分期区别主要在T3a期,T3a期分为T3a-CT(10例)和T3a-仅病理(6例),T3a-仅病理CT分期可分为T1期2例,T2期4例;单因素分析显示,肿瘤大小、肿瘤是否侵及肾被膜外、是否侵及肾窦集合系统、是否侵及肾静脉及分支、是否侵及下腔静脉、有无广泛性坏死、是否存在囊性改变、瘤周是否受侵、瘤周是否存在新生血管与5年生存率具有一定相关性(P<0.05);多因素回归分析显示,肿瘤≥7cm、肿瘤穿透肾被膜、肾静脉及分支受侵、下腔静脉受侵、肿瘤无囊变、瘤周受侵及瘤周新生血管是影响肾透明细胞癌预后的独立危险因素(P<0.05)。结论肾透明细胞瘤患者肿瘤大于7cm、肿瘤穿透肾被膜、肾静脉及分支受侵、下腔静脉受侵、肿瘤无囊变、瘤周受侵及瘤周新生血管是影响肾透明细胞癌预后的独立危险因素,肿瘤周围受侵及瘤周新生血管形成可降低患者5年生存率,而肿瘤囊变可作为预测术后康复情况较好的标志之一。 相似文献
5.
《Diagnostic and interventional imaging》2021,102(10):629-639
PurposeTo investigate the reproducibility of diffusion-weighted (DW) MRI and 18F-Fluorodeoxyglucose (18F-FDG)-Positron emission tomography/CT (PET/CT) in monitoring response to neoadjuvant chemotherapy in epithelial ovarian cancer.Materials and methodsTen women (median age, 67 years; range: 41.8–77.3 years) with stage IIIC-IV epithelial ovarian cancers were included in this prospective trial (NCT02792959) between 2014 and 2016. All underwent initial laparoscopic staging, four cycles of carboplatine-paclitaxel-based chemotherapy and interval debulking surgery. PET/CT and DW-MRI were performed at baseline (C0), after one cycle (C1) and before surgery (C4). Two nuclear physicians and two radiologists assessed five anatomic sites for the presence of ≥ 1 lesion. Target lesions in each site were defined and their apparent diffusion coefficient (ADC), maximal standardized uptake value (SUV-max), SUV-mean, SUL-peak, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were monitored (i.e., 10 patients × 5 sites × 3 time-points). Their relative early and late changes were calculated. Intra/inter-observer reproducibilities of qualitative and quantitative analysis were estimated with Kappa and intra-class correlation coefficients (ICCs).ResultsFor both modalities, inter- and intra-observer agreement percentages were excellent for initial staging but declined later for DW-MRI, leading to lower Kappa values for inter- and intra-observer variability (0.949 and 1 at C0, vs. 0.633 and 0.643 at C4, respectively) while Kappa values remained > 0.8 for PET/CT. Inter- and intra-observer ICCs were > 0.75 for SUV-max, SUL-peak, SUV-mean and their change regardless the time-point. ADC showed lower ICCs (range: 0.013–0.811). ANOVA found significant influences of the evaluation time, the measurement used (ADC, SUV-max, SUV-mean, SUV-max, SUL-peak, MTV or TLG) and their interaction on ICC values (P = 0.0023, P< 0.0001 and P =0.0028, respectively).ConclusionWhile both modalities demonstrated high reproducibility at baseline, only SUV-max, SUL-peak, SUV-mean and their changes maintained high reproducibility during chemotherapy. 相似文献
6.
目的:基于原发肿瘤及淋巴结CT特征建立评分模型预测食管鳞癌患者喉返神经旁淋巴结(RLN-LN)转移风险。方法:回顾性收集2014年1月至2019年12月于北京大学肿瘤医院行食管癌根治术并清扫RLN-LN的92例食管鳞癌患者。根据术后淋巴结病理结果分为RLN-LN转移组(n=37)和非转移组(n=55)。评估术前CT图像,记录食管癌患者年龄、性别、分化程度、肿瘤位置、肿瘤大小(肿瘤长度、肿瘤厚度、厚度/长度)、RLN-LN大小(淋巴结短径、长径、短径/多平面重建(MPR)最长径]。采用多元logistic回归筛选独立预测因子并建立评分模型,采用ROC曲线评估评分模型及独立预测因子诊断RLN-LN转移的效能,采用Z检验比较曲线下面积(AUC)的差异。应用Hosmer-Lemeshow检验和校准曲线评估模型拟合度。结果:肿瘤位置、肿瘤长度、RLN-LN短径、短径/MPR最长径是RLN-LN转移的独立预测因子,其诊断RLN-LN转移的AUC分别为0.586、0.705、0.831、0.777。基于以上4个CT特征建立评分模型,评分模型诊断RLN-LN转移的AUC为0.903(95%CI 0.846~0.959),优于各单一CT特征(Z=5.812,P<0.001;Z=2.161,P=0.030;Z=2.929,P=0.003;Z=4.052,P<0.001)。拟合优度Hosmer-Lemeshow检验结果显示P=0.555,校准曲线提示评分模型预测RLN-LN转移风险与实际转移风险之间具有良好的一致性。结论:基于CT图像的评分模型有助于食管鳞癌RLN-LN转移状态危险分层。 相似文献
7.
8.
《European journal of surgical oncology》2022,48(7):1650-1655
PurposeTo examine the annual hospital volume of surgery in relation to survival in colorectal cancer. Previous studies on hospital volume and survival following colorectal cancer surgery are conflicting.MethodsAll 49 032 patients who underwent resection for colorectal cancer in 1987–2016 in Finland were included, with complete follow-up until December 31, 2019. Primary outcome was 5-year mortality. Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI) for quartiles of annual hospital volume for colorectal surgery, adjusted for calendar period, age, sex, comorbidity, stage, tumor location and oncological therapy. Additionally, colon and rectal cancer surgery were assessed separately. Sensitivity analysis of patients with confirmed curative intent was conducted.ResultsCompared to highest quartile (≥108 resections annually), lowest hospital volume (≤37 resections annually) was associated with slightly increased 5-year all-cause mortality (adjusted HR 1.07, 95% CI 1.02–1.12). A pre-planned subgroup-analysis suggested a slightly improved 5-year survival in high-volume institutions for rectal cancer, but not colon cancer surgery. Sensitivity analysis including only those operated with confirmed curative intent suggested no differences between hospital volume groups in colorectal, colon or rectal cancer for 5-year all-cause mortality.ConclusionHigher hospital volume is associated with slightly improved all-cause 5-year mortality in colorectal cancer surgery, but this effect may be limited to rectal cancer surgery only. Volume-outcome relationship in rectal cancer surgery should be investigated further using large datasets. These results do not support centralization of colon cancer surgery based on hospital volume only. 相似文献
9.
目的探讨肝内胆管细胞癌(ICC)行根治性切除(R0切除)术后的独立预后影响因素。
方法回顾性分析中山大学附属第一医院自2002年1月至2018年8月行R0切除并经病理确诊的237例ICC患者的临床病理及随访资料,采用Kaplan-Meier法构建生存曲线;单因素及多因素COX回归分析筛选影响患者生存预后的独立因素。一致性指数(C-index)、时间依赖性受试者工作特征曲线(ROC曲线)、曲线下面积(AUC)及校准曲线用于评价COX回归模型的预测效能。
结果237例ICC患者的中位生存期为19.93个月(95%CI=14.31~26.21),术后1、2、3年生存率分别为62.3%、45.0%及35.6%。单因素及多因素回归分析显示谷氨酰转移酶(GGT) >53 U/L(P=0.001)、CA125>17.4 U/ml(P<0.001)、淋巴结转移(P=0.039)、肿瘤分化不良(P<0.001)是ICC患者行R0切除术后预后不良的独立危险因素。按照删除概率P>0.1的标准,纳入癌胚抗原(CEA)(P=0.092)后的预后模型C-index为0.74(95%CI=0.68~0.78),不同随访时间点对应的AUC值均在0.8左右,模型具有良好的预测效能。
结论GGT、CEA、CA125、淋巴结转移情况及肿瘤分化程度可作为ICC患者R0切除术后临床预后的预测指标。 相似文献
10.
随着腹腔镜肝切除技术的发展与推广,腹腔镜肝切除中的一些难点,如术中出血的控制、解剖性肝切除、巨大肝癌切除、腹腔镜下联合肝脏分割与门静脉支结扎的二步肝切除术(ALPPS)等方面均基本解决。术中超声与荧光染色技术也得到普及。本文就上述问题做一概述,并对腹腔镜肝切除未来发展提出思路,以进一步推动我国腹腔镜肝切除的技术进步。 相似文献